Day One Biopharmaceuticals, Inc. (DAWN)
Price:
10.57 USD
( - -0.36 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
Atara Biotherapeutics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
NEWS
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-25 06:11:30Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
zacks.com
2026-02-24 20:31:53Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.69 per share a year ago.
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
globenewswire.com
2026-02-24 16:00:00OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif.
Will Day One Biopharmaceuticals, Inc. (DAWN) Report Negative Earnings Next Week? What You Should Know
zacks.com
2026-02-17 11:01:49Day One Biopharmaceuticals (DAWN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
globenewswire.com
2026-02-10 08:30:00BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m.
Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
zacks.com
2026-02-02 10:55:33The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Best Momentum Stocks to Buy for January 27th
zacks.com
2026-01-27 11:02:06SHOO, DAWN and MCHP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 27th, 2026.
New Strong Buy Stocks for January 27th
zacks.com
2026-01-27 05:21:05SNDK, SHOO, DAWN, EFXT and MCHP have been added to the Zacks Rank #1 (Strong Buy) List on January 27th, 2026.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet
zacks.com
2026-01-15 10:55:57The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 107.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
zacks.com
2026-01-13 10:25:29Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-13 00:35:59Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
globenewswire.com
2026-01-11 17:00:00Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif.
Day One Completes Acquisition of Mersana Therapeutics
globenewswire.com
2026-01-06 09:02:00BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the successful close of its acquisition of Mersana Therapeutics, Inc., (NASDAQ: MRSN) (“Mersana”) following completion of all conditions of the tender offer to acquire all outstanding shares of Mersana at a price of $25 per share in cash, plus one non-tradable contingent value right (“CVR”) per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
defenseworld.net
2026-01-02 01:38:56Shares of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)
globenewswire.com
2025-12-23 15:19:01BALA CYNWYD, Pa. , Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith.
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish
seekingalpha.com
2025-12-18 15:46:43Day One Biopharmaceuticals, Inc. is gaining momentum after Ojemda's strong Q3 launch, with revenues up 15% sequentially and full-year guidance raised to $145–$150m. DAWN's Ojemda is the only therapy specifically approved for PLGG, with a chance to become standard of care and ongoing Phase 3 front-line study. Strategic moves include acquiring Mersana Therapeutics for ADC pipeline expansion and a lucrative partnership with Ipsen for ex-US commercialization.
No data to display
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-25 06:11:30Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
zacks.com
2026-02-24 20:31:53Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.69 per share a year ago.
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
globenewswire.com
2026-02-24 16:00:00OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif.
Will Day One Biopharmaceuticals, Inc. (DAWN) Report Negative Earnings Next Week? What You Should Know
zacks.com
2026-02-17 11:01:49Day One Biopharmaceuticals (DAWN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
globenewswire.com
2026-02-10 08:30:00BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m.
Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
zacks.com
2026-02-02 10:55:33The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Best Momentum Stocks to Buy for January 27th
zacks.com
2026-01-27 11:02:06SHOO, DAWN and MCHP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 27th, 2026.
New Strong Buy Stocks for January 27th
zacks.com
2026-01-27 05:21:05SNDK, SHOO, DAWN, EFXT and MCHP have been added to the Zacks Rank #1 (Strong Buy) List on January 27th, 2026.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet
zacks.com
2026-01-15 10:55:57The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 107.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
zacks.com
2026-01-13 10:25:29Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-13 00:35:59Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
globenewswire.com
2026-01-11 17:00:00Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at 5:15 pm PT (8:15 pm ET) BRISBANE, Calif.
Day One Completes Acquisition of Mersana Therapeutics
globenewswire.com
2026-01-06 09:02:00BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the successful close of its acquisition of Mersana Therapeutics, Inc., (NASDAQ: MRSN) (“Mersana”) following completion of all conditions of the tender offer to acquire all outstanding shares of Mersana at a price of $25 per share in cash, plus one non-tradable contingent value right (“CVR”) per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
defenseworld.net
2026-01-02 01:38:56Shares of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN - Get Free Report) have been given an average rating of "Moderate Buy" by the nine analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)
globenewswire.com
2025-12-23 15:19:01BALA CYNWYD, Pa. , Dec. 23, 2025 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith.
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish
seekingalpha.com
2025-12-18 15:46:43Day One Biopharmaceuticals, Inc. is gaining momentum after Ojemda's strong Q3 launch, with revenues up 15% sequentially and full-year guidance raised to $145–$150m. DAWN's Ojemda is the only therapy specifically approved for PLGG, with a chance to become standard of care and ongoing Phase 3 front-line study. Strategic moves include acquiring Mersana Therapeutics for ADC pipeline expansion and a lucrative partnership with Ipsen for ex-US commercialization.